GLP-1 medications pulled a wave of clinicians (and plenty of non-clinician founders) into medical weight loss. Semaglutide and tirzepatide have well-established titration protocols, so the clinical playbook is not the hard part. What separates a clinic that runs smoothly from one that drowns in refunds, refill requests, and regulatory exposure is everything around the prescription. Whether you arrive as a clinician who wants to own the practice or as a non-clinician founder planning to hire prescribers, the legal structure that makes your path work is different, which is why structure comes first: before branding, before the website, before the pharmacy account. This guide walks through the five decisions that matter, in sequence.
Step 1: Get the legal structure right before anything else
If you are a physician, you can generally own the practice directly and this step is short. If you are not, you run into the corporate practice of medicine (CPOM) doctrine: in a large number of states, only a licensed physician (or in some states, other licensed clinicians) may own an entity that practices medicine. A non-physician who simply forms an LLC and hires a doctor is, in those states, running an illegal structure, one that can void contracts, jeopardize the clinician's license, and become very expensive to unwind after the fact.
The standard workaround is the MSO model: a physician-owned professional corporation (PC or PLLC) employs the clinicians and owns the medical decisions, while a separate management services organization (which the founder can own) provides the brand, marketing, software, staffing, billing support, and space in exchange for a management fee. Done correctly, the physician controls clinical care and the MSO runs the business around it. Done sloppily, with fee structures that amount to fee-splitting or management agreements that let the MSO direct care, it recreates the exact problem it was built to avoid.
Where NPs and PAs land depends on the state. In full-practice-authority states, an NP can often own the practice and prescribe independently; in reduced- or restricted-practice states, a collaborating physician is required, and the ownership question gets state-specific fast. The rules do not sort into one tidy axis: some states are permissive on ownership and strict on supervision, others the reverse. We cover the mechanics, including how management fees typically get structured, in our companion guide to MSO and corporate-practice-of-medicine structures. Whatever you read here or there: have a healthcare attorney in your state paper the entities before you see patient one.
Step 2: Design the clinical model
The initial visit
A defensible GLP-1 program starts with a real evaluation, not a checkout page. That typically means a good-faith exam covering history, medication review, and screening against the contraindications in the drug's prescribing information, plus baseline labs (most operators order at least a metabolic panel, lipids, and HbA1c; your protocol may add more). The visit establishes the clinician-patient relationship, documents medical necessity, and produces the baseline you will measure progress against.
Titration and follow-up
GLP-1s are titrated: patients start at a low dose and step up on a schedule (commonly every four weeks) as tolerated, until they reach a maintenance dose. Operationally, that means every patient generates a recurring stream of dose changes, side-effect check-ins, and refill events, each of which needs to be documented. Most clinics run monthly touchpoints during titration and space visits out at maintenance. The clinics that struggle are the ones that treat this as a one-time transaction instead of a longitudinal protocol; the chart has to show the titration story, not just the first script.
Staff the triage layer deliberately: an MA or RN working from written protocols can field the routine flood of nausea, constipation, and injection-site questions, resolving most of them without interrupting the prescriber. Put the escalation path in writing, including which symptoms (severe abdominal pain, persistent vomiting, allergic reactions) go straight to the prescriber and how quickly. If every message defaults to the prescriber, message volume becomes your growth ceiling.
Telehealth vs in-person: a spectrum
Few clinics should sit at either extreme. The range runs from fully virtual (video consults, medication shipped to the patient, lowest overhead, license required in every state where your patients sit) through hybrid (initial visit in person or on video, follow-ups virtual) to office-based (in-person visits, in-office weigh-ins and body composition, sometimes in-office administration of the first injection to teach technique). Virtual scales geographically; in-person tends to retain better and supports upsells like body-composition tracking. Many successful clinics start hybrid in one state and expand from there.
Step 3: Decide how you'll source medication
This is the decision with the most regulatory motion, so hold it loosely. As of August 2026, the default brand path runs through the manufacturers' own cash channels, and compounded supply has narrowed to an exception rather than a strategy.
Brand-name via manufacturer direct-to-consumer programs. Both manufacturers now sell to self-pay patients at prices far below the old retail sticker. LillyDirect sells Zepbound (tirzepatide) single-dose vials at $299–$449/month depending on dose, and since February 2026 offers auto-injector pens at the same tiers (it is a self-pay program, and refill-window conditions apply). NovoCare Pharmacy sells the Wegovy (semaglutide) pen at $349/month for standard doses and an oral Wegovy tablet at $149–$299/month by dose. TrumpRx.gov, launched in February 2026, lists both at roughly $346–$350 on average. Those prices are current as of mid-2026; confirm them before quoting patients. Operationally this is the simplest path: you e-prescribe, the manufacturer-affiliated pharmacy ships, and the clinic never touches the drug. Insurance coverage for weight loss indications remains inconsistent, which is exactly why these cash programs now anchor the market.
Compounded semaglutide and tirzepatide built the first wave of cash-pay GLP-1 clinics, but that window has largely closed. The timeline is worth stating plainly: the FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage in February 2025, and the enforcement grace periods ended in spring 2025 (March 2025 for 503B tirzepatide, April and May 2025 for semaglutide). Since then, routine compounding of these drugs is largely impermissible: it is barred for 503B outsourcing facilities, and 503A pharmacies may compound only for an individual patient whose prescriber documents a clinically significant difference from the approved product (patient preference or cost alone is not sufficient). In April 2026 the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Enforcement is active: dozens of warning letters went to telehealth marketers in late 2025, and a major telehealth company settled with Novo Nordisk and exited compounded semaglutide in March 2026. Compounders' lawsuits challenging the shortage determinations failed in district court; appeals are pending, but no injunction currently protects continued compounding. Two things every operator must still internalize. First, compounded drugs are not FDA-approved (no compounded medication is), and you should never market them as if they were. Second, this status has changed repeatedly and will keep changing, so do not take this guide as a statement that compounding any particular drug is permitted today. Verify with your pharmacy partners and counsel at the time you order.
Where compounding remains defensible, you will also hit the 503A vs 503B distinction: 503A pharmacies compound against patient-specific prescriptions you send them, while 503B outsourcing facilities supply office stock a clinic administers on site (and are currently barred from compounding these GLP-1s at all). Which one you use shapes your ordering workflow and your inventory obligations. The full breakdown is in our 503A vs 503B guide.
Brand vs compounded: the trade-offs
| Brand (Wegovy / Zepbound) | Compounded (semaglutide / tirzepatide) | |
|---|---|---|
| FDA approval | Yes (approved products) | No. Compounded drugs are not FDA-approved |
| Patient cost | $299–$449/month via manufacturer self-pay programs, as of mid-2026 | Historically lower; now limited to narrow 503A exceptions |
| Availability | Manufacturer supply; shortages resolved since early 2025 | Largely impermissible since spring 2025; verify current policy |
| Delivery format | Manufacturer auto-injector pens | Typically vials + syringes; patient education needed |
| Clinic workflow | E-prescribe; pharmacy handles the rest | Pharmacy relationships, lot tracking if office stock |
| Regulatory risk | Lower (standard prescribing) | Higher and shifting. Requires ongoing counsel |
| Insurance interplay | Some patients get pharmacy coverage | Cash only |
When your supply chain breaks
Operators who ran clinics through 2024–25 ask this question of any new clinic plan before any other, because most of them lived it. Build three things before you need them. First, a second pharmacy relationship, credentialed and tested, so one supplier's decision cannot strand your patient panel. Second, a written transition protocol for moving patients brand-to-compound or compound-to-brand: dose-equivalence guidance from your prescriber, a fresh consent covering the switch, and repricing rules decided in advance rather than negotiated patient by patient. Third, a patient-communications plan: templated messages explaining what changed, what it costs now, and what happens to the next dose. Clinics that had these ready in early 2025 kept their panels; clinics that improvised spent months rebuilding trust.
Step 4: Pick a pricing model
Cash-pay is the default in this niche, and it is a feature, not a compromise: no payer contracts, no prior authorizations, no claim denials, no 90-day receivables. You set the price, the patient pays it, and your revenue arrives when the service does. If you are still weighing whether to take insurance at all, our cash-pay vs insurance guide covers that decision in depth. The two dominant structures:
- All-inclusive monthly membership. One recurring price covers the visits, the medication (usually compounded), and messaging support. Simple to sell, predictable revenue, and the model most cash-pay GLP-1 programs use, commonly landing somewhere in the $300–$600/month range depending on the drug, the dose, and the market. Titration creates a wrinkle: higher doses cost you more, so decide up front whether the price is flat or dose-tiered. One legal note: a clinic charging patients for medication implicates state physician-dispensing and pharmacy rules; confirm your state permits your dispensing model before pricing it in.
- Visit fee + medication separately. The clinic charges for the consult and follow-ups; the patient buys medication at the pharmacy (often brand-name, sometimes with their pharmacy insurance). Cleaner margins on your time, no drug-cost exposure, but a bumpier patient experience and more price sensitivity at the pharmacy counter.
Price against the market patients actually see: telehealth discounters have pushed the floor to roughly $149–$249/month, and patients comparison-shop against manufacturer-direct pricing of $299–$449/month (as of August 2026), so a local clinic in the $300–$600 band justifies its premium with supervision, in-person exams, labs, and body-composition tracking, not with access to the drug itself.
Neither is "correct." Membership models optimize for retention and lifetime value; unbundled models optimize for simplicity and lower regulatory surface. Whichever you choose, write your pause, cancellation, and refund policies before launch. Weight loss programs generate more billing disputes from patients who quit mid-titration than from anything else.
Step 5: Build the software stack
A GLP-1 clinic is operationally a subscription business wrapped around a longitudinal clinical protocol. The tooling has to cover both halves:
- Online booking. Patients discovering you through ads expect to self-schedule, not call.
- Intake forms: medical history and screening collected before the visit, feeding the chart.
- Charting built for titration: dose history, weight trend, side effects, and the good-faith exam, visible at a glance rather than buried across visit notes.
- E-prescribing to retail and compounding pharmacies, from inside the chart.
- Patient messaging. Dose questions, injection-site questions, and nausea questions are constant between visits; if this runs through personal texting you have both a burnout problem and a HIPAA problem.
- Recurring billing and memberships: automated monthly charges, dunning for failed cards, pause and cancel flows.
- Inventory. If you administer in office from 503B stock, you need lot-level tracking with expiration dates tied to the patient record.
One honest plug: stitching those together from five point solutions is how most new clinics end up with data in five places. Moonshot Clinic bundles scheduling, patient messaging, charting, e-prescribing, membership billing, and inventory in one platform, and it was built by an operator who runs his own GLP-1 and hormone practice on it. See how it works for GLP-1 clinics.
Compliance pitfalls that catch new operators
Advertising claims. Never guarantee weight loss, a specific number of pounds, or a timeline. Regulators treat weight loss advertising as a priority category, and "results not typical" fine print does not fix a misleading headline. Market the program and the supervision, not promised outcomes, and never describe compounded drugs as FDA-approved.
Questionnaire-only prescribing. Prescribing off an async form with no real evaluation is the pattern state boards go after. Do a genuine good-faith exam (video counts in most states), document it, and be able to show why each patient was an appropriate candidate.
Controlled-substance creep. GLP-1s are not controlled substances, so no DEA registration is needed to prescribe them. But most weight loss clinics eventually add adjacent services. Testosterone is Schedule III, and some adjunct medications are scheduled too. The moment you add one, you inherit DEA registration, inventory reconciliation, and recordkeeping obligations your GLP-1-only workflow never had. Decide early whether your systems can grow into that.
Records retention. Every state sets a minimum retention period for medical records, and in a subscription practice the "record" includes the message threads where dosing decisions actually happened. Keep charts, messages, and billing records retrievable for at least your state's minimum (longer for minors), and make sure your platform can export them if you ever migrate.
This guide is general information for clinic operators, not legal, medical, or regulatory advice. Corporate-practice-of-medicine rules, scope-of-practice laws, telehealth standards, and FDA policy on compounded GLP-1s all vary by state and change over time. Consult a healthcare attorney licensed in your state and your own clinical and pharmacy partners before forming entities, prescribing, or sourcing medication.